Literature DB >> 26659801

In Situ Sodium Bisulfite Modification of Genomic DNA from Microdissected Melanoma Paraffin-Embedded Archival Tissues.

Diego M Marzese1, Sharon K Huang1, Dave S B Hoon2.   

Abstract

DNA methylation analysis of paraffin-embedded archival tumor tissues (PEAT) is important in clinical and translational research studies. Efficient identification and isolation of homogeneous cell population, optimal DNA extraction, and sodium bisulfite modification (SBM) are essential, particularly in small tumor lesions. Laser capture microdissection (LCM) coupled with an in situ SBM improves the specificity, through histopathology accuracy, and the amount of genomic DNA modified for downstream methylation assays.

Entities:  

Keywords:  DNA methylation; Laser capture microdissection (LCM); Melanoma; Sodium bisulfite modification (SBM)

Year:  2015        PMID: 26659801      PMCID: PMC5329140          DOI: 10.1007/7651_2015_303

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  13 in total

1.  The role of DNA methylation in mammalian epigenetics.

Authors:  P A Jones; D Takai
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

2.  Bisulfite genomic sequencing: systematic investigation of critical experimental parameters.

Authors:  C Grunau; S J Clark; A Rosenthal
Journal:  Nucleic Acids Res       Date:  2001-07-01       Impact factor: 16.971

3.  Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study.

Authors:  Anneke Q van Hoesel; Cornelis J H van de Velde; Peter J K Kuppen; Gerrit Jan Liefers; Hein Putter; Yusuke Sato; David A Elashoff; Roderick R Turner; Jaime M Shamonki; Esther M de Kruijf; Johanna G H van Nes; Armando E Giuliano; Dave S B Hoon
Journal:  Breast Cancer Res Treat       Date:  2012-04-05       Impact factor: 4.872

Review 4.  Laser capture microdissection in the tissue biorepository.

Authors:  Angen Liu
Journal:  J Biomol Tech       Date:  2010-09

5.  Analysis of methylated circulating DNA in cancer patients' blood.

Authors:  Eiji Sunami; Anh-Thu Vu; Sandy L Nguyen; Dave S B Hoon
Journal:  Methods Mol Biol       Date:  2009

6.  Human DNA methylomes at base resolution show widespread epigenomic differences.

Authors:  Ryan Lister; Mattia Pelizzola; Robert H Dowen; R David Hawkins; Gary Hon; Julian Tonti-Filippini; Joseph R Nery; Leonard Lee; Zhen Ye; Que-Minh Ngo; Lee Edsall; Jessica Antosiewicz-Bourget; Ron Stewart; Victor Ruotti; A Harvey Millar; James A Thomson; Bing Ren; Joseph R Ecker
Journal:  Nature       Date:  2009-10-14       Impact factor: 49.962

7.  Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles.

Authors:  Michiel F G de Maat; Naoyuki Umetani; Eiji Sunami; Roderick R Turner; Dave S B Hoon
Journal:  Mol Cancer Res       Date:  2007-05       Impact factor: 5.852

Review 8.  PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment.

Authors:  Lasse Sommer Kristensen; Lise Lotte Hansen
Journal:  Clin Chem       Date:  2009-06-11       Impact factor: 8.327

9.  LINE-1 hypomethylation during primary colon cancer progression.

Authors:  Eiji Sunami; Michiel de Maat; Anna Vu; Roderick R Turner; Dave S B Hoon
Journal:  PLoS One       Date:  2011-04-14       Impact factor: 3.240

10.  Cause and consequences of genetic and epigenetic alterations in human cancer.

Authors:  B Sadikovic; K Al-Romaih; J A Squire; M Zielenska
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

View more
  1 in total

1.  CDKN2B, SLC19A3 and DLEC1 promoter methylation alterations in the bone marrow of patients with acute myeloid leukemia during chemotherapy.

Authors:  Qingxiao Hong; Yirun Li; Xiaoying Chen; Huadan Ye; Linlin Tang; Annan Zhou; Yan Hu; Yuting Gao; Rongrong Chen; Yongming Xia; Shiwei Duan
Journal:  Exp Ther Med       Date:  2016-02-19       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.